Skip to content

Walnut Shell Glasses Moxibustion for Dry Eye Syndrome

Walnut Shell Glasses Moxibustion for Dry Eye Syndrome: a Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03116776
Enrollment
128
Registered
2017-04-17
Start date
2017-05-01
Completion date
2018-12-30
Last updated
2018-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye

Keywords

walnut shell glasses moxibustion, dry eye, randomized controlled trial

Brief summary

This trial is designed to evaluate the efficacy of walnut shell glasses moxibustion for dry eye syndrome compared with sodium hyaluronate eye drops.

Interventions

PROCEDUREWalnut Shell Glasses Moxibustion

Participants in experimental group will receive 12 sessions of walnut shell glasses moxibustion, each for 30 minutes,3 times per week, and administered over 4 weeks.

One drop for each eye, four times per day for over 4 weeks.

Sponsors

Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

outcome assessor and statistician will be blinded

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. eyes are in line with dry eye diagnostic criteria. 2. Age 18 to 75 years, 3. signed informed consent, voluntary adherence to treatment for more than 1 month.

Exclusion criteria

1. combined with other eye disease (such as conjunctiva, cornea and iris have significant lesions). 2. eye surgery within 3 months. 3. pregnant or lactating women. 4. oral the drugs which could inhibit lacrimal gland secretion. 5. severe meibomian gland dysfunction. 6. severe eye burns, chemical injury patients. 7. combined with cardiovascular and cerebrovascular, liver, kidney and hematopoietic system and other serious primary disease, mental patients. 8. patients with Sjogren's syndrome. 9. patients who are participating in other drug clinical trials. 10. patients who are using other drugs or therapies for the treatment of dry eyes.

Design outcomes

Primary

MeasureTime frameDescription
change from baseline in OSDI scoreweek 4, week 16, week 28We use the ocular surface disease index(OSDI) to evaluate the degree of dry eye. Assessing time point: at week 4, week 16, week 28.

Secondary

MeasureTime frameDescription
change from baseline in mean weekly OSDI scoreweek 1-4, week 16, week 28The mean weekly OSDI score over weeks 1-4 will be calculated as as the sum of each week divided by the number of weeks assessed.
change from baseline in VAS of eye discomfortweek 4, week 16, week 28Eye discomfort VAS scale: for the eye symptoms of self-assessment. Dry eye symptoms include itching, foreign body sensation, burning sensation, pain, dry, blurred vision, photophobia, eye swelling, tear Crack,ect. The overall discomfort are evaluate by VAS . Uses a 100-mm line that is labeled at each end. 0 mm represents no eye discomfort, 100 mm represents the most intolerable eye discomfort. Patient will rate the VAS(average VAS in the past 24h three times a week).
change from baseline in mean daily VAS scoreweek 1-4, week 16, week 28Patients will rate their average eye comfort with VAS three times a week. The mean daily VAS over week 1-4 will be calculated as the sum of each day divided by the number of days assessed.
the efficacy of Walnut Shell Glasses Moxibustionweek 4, week 16, week 28The proportion of patients whose OSDI score reduced more than 50%
change from baseline in SchimerⅠtextweek 2, week 4Evaluation the tear secretion, do not use ocular surface anesthetic, measuring the amount of reflex tear secretion. Place the test paper in the middle and outer 1/3 of the conjunctiva of the lower eyelid, and instruct the patient to lighten his eyes or look down at the bottom, and remove it after 5 minutes to measure the wetness from the beginning of the bend.
change from baseline in corneal fluorescence staining scoresweek 2, week 4Corneal fluorescein staining: 2% fluorescein sodium coated with glass rods in the conjunctival sac, observed under the slit lamp to observe whether the corneal epithelium with staining, such as yellow-green stained, suggesting that corneal epithelial cell integrity damage. Score by 12 points. Cornea was divided into 4 quadrants, each quadrant was 0-3, no staining was 0, 1 to 30 dotted was 1 point, \> 30 dotted but not fused For 2 points, 3 points for the emergence of corneal punctate staining, filaments and ulcers.
patiant's expectations for moxibustionbaselineThis questionnaire includes three brief questions to investigate whether patients believe that moxibustion treatment will be useful. The relationship between patients' expectations and the effectiveness of moxibustion will be investigated because patients' beliefs about treatment enhanced or attenuated the effectiveness of treatment in a previous experimental study .
change from baseline in BUTweek 2, week 4Check the tear break time(BUT) should be carried out before the other steps in the operation of the eye, used to evaluate the stability of the tear film. In the room without air flow, 1% of the sodium fluorescein with a glass rod dipped in a little coating in the lower eyelid conjunctival sac, the patient after several times, through the slit lamp cobalt blue light wide band inspection tear film, with a stopwatch Record the last time after the completion of the first blink of an eye to open to the tear film appeared in the first randomly distributed dry spots or black lines of time, recorded three times to take the mean.

Countries

China

Contacts

Primary ContactWeiwei Fu
fuweiwei_vm@163.com+86-15201309895
Backup ContactZhishun Liu
liuzhishun@aliyun.com+86-10-88001124

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026